Interview: BioNTech And Pfizer Explore mRNA Flu Vaccines In $120m+ Deal
Executive Summary
The German biotech's CBO and CCO Sean Marett tells Scrip that the Pfizer pact represents the first time BioNTech has moved into infectious disease in humans and could lead to higher potency flu vaccines that could be made more rapidly and cheaply.
You may also be interested in...
Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April
The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.
mRNA Vaccines – Trials Line Up Against Coronavirus
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
mRNA Vaccines – A Novel Weapon Against Coronavirus
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.